SPRY
ARS Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
3.79 / 10
Netural
Analyst sentiment is overwhelmingly bullish (Strong Buy at 100%) based on a single report from Roth Capital, yet the historical win-rate is 0.0%, raising doubts about reliability. Fund-flow data show a good aggregate score (7.59/10) but negative trends at every scale (block, small, medium, large, extra-large), suggesting money is entering but not decisively. This disconnect between positive flow and negative trend, coupled with sparse analyst coverage, warrants caution in interpreting bullish signals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-04
InstitutionRoth Capital
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of SPRY?
- SPRY holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.79/10 (Netural).
